Similarly, the Naohiro Yoshida et al. study examined primary tumours from 199 stage II–III CRC patients and found that the Foxp3/CD3 ratio did not correlate with metastasis or prognosis. The gene discussed is FOXP3; the disease is colorectal carcinoma.